Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Douglas C. A. Taylor; Ankur Pandya; David Thompson; Paula Chu; Jennifer Graff; James Shepherd; Nanette Wenger; Heiner Greten; Rafael Carmena; Michael Drummond; Milton C. Weinstein

doi:10.1007/s10198-008-0126-1

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Douglas C. A. Taylor, Ankur Pandya, David Thompson, Paula Chu, Jennifer Graff, James Shepherd, Nanette Wenger, Heiner Greten, Rafael Carmena, Michael Drummond, Milton C. Weinstein

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to 10 mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding costs of care, when compared to the A10 treatment, in all three countries. The incremental cost per QALY gained was a,not sign 9,500, a,not sign 21,000, and a,not sign 15,000 in the UK, Spain, and Germany, respectively. Intensive A80 treatment is estimated to be cost-effective when compared to A10 treatment in secondary cardiovascular prevention.

Original language	English
Pages (from-to)	255-265
Number of pages	11
Journal	European Journal of Health Economics
Volume	10
Issue number	3
DOIs	https://doi.org/10.1007/s10198-008-0126-1
Publication status	Published - Jul 2009

Keywords

Cardiovascular disease
Cholesterol lowering
Cost-effectiveness
Decision analysis
Markov model
Secondary prevention
Statin therapy
SCANDINAVIAN SIMVASTATIN SURVIVAL
CORONARY-HEART-DISEASE
MYOCARDIAL-INFARCTION
CHOLESTEROL LEVELS
CONTROLLED-TRIAL
FOLLOW-UP
4S
PRAVASTATIN
GUIDELINES
PROGNOSIS

Access to Document

10.1007/s10198-008-0126-1

Cite this

Taylor, D. C. A., Pandya, A., Thompson, D., Chu, P., Graff, J., Shepherd, J., Wenger, N., Greten, H., Carmena, R., Drummond, M., & Weinstein, M. C. (2009). Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. European Journal of Health Economics, 10(3), 255-265. https://doi.org/10.1007/s10198-008-0126-1

@article{d421bdad95204e2a876f14d04671f4bf,

title = "Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study",

abstract = "The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to 10 mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding costs of care, when compared to the A10 treatment, in all three countries. The incremental cost per QALY gained was a,not sign 9,500, a,not sign 21,000, and a,not sign 15,000 in the UK, Spain, and Germany, respectively. Intensive A80 treatment is estimated to be cost-effective when compared to A10 treatment in secondary cardiovascular prevention.",

keywords = "Cardiovascular disease, Cholesterol lowering, Cost-effectiveness, Decision analysis, Markov model, Secondary prevention, Statin therapy, SCANDINAVIAN SIMVASTATIN SURVIVAL, CORONARY-HEART-DISEASE, MYOCARDIAL-INFARCTION, CHOLESTEROL LEVELS, CONTROLLED-TRIAL, FOLLOW-UP, 4S, PRAVASTATIN, GUIDELINES, PROGNOSIS",

author = "Taylor, {Douglas C. A.} and Ankur Pandya and David Thompson and Paula Chu and Jennifer Graff and James Shepherd and Nanette Wenger and Heiner Greten and Rafael Carmena and Michael Drummond and Weinstein, {Milton C.}",

year = "2009",

month = jul,

doi = "10.1007/s10198-008-0126-1",

language = "English",

volume = "10",

pages = "255--265",

journal = "European Journal of Health Economics",

issn = "1618-7598",

publisher = "Springer",

number = "3",

}

Taylor, DCA, Pandya, A, Thompson, D, Chu, P, Graff, J, Shepherd, J, Wenger, N, Greten, H, Carmena, R, Drummond, M & Weinstein, MC 2009, 'Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study', European Journal of Health Economics, vol. 10, no. 3, pp. 255-265. https://doi.org/10.1007/s10198-008-0126-1

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. / Taylor, Douglas C. A.; Pandya, Ankur; Thompson, David et al.
In: European Journal of Health Economics, Vol. 10, No. 3, 07.2009, p. 255-265.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

AU - Taylor, Douglas C. A.

AU - Pandya, Ankur

AU - Thompson, David

AU - Chu, Paula

AU - Graff, Jennifer

AU - Shepherd, James

AU - Wenger, Nanette

AU - Greten, Heiner

AU - Carmena, Rafael

AU - Drummond, Michael

AU - Weinstein, Milton C.

PY - 2009/7

Y1 - 2009/7

N2 - The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to 10 mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding costs of care, when compared to the A10 treatment, in all three countries. The incremental cost per QALY gained was a,not sign 9,500, a,not sign 21,000, and a,not sign 15,000 in the UK, Spain, and Germany, respectively. Intensive A80 treatment is estimated to be cost-effective when compared to A10 treatment in secondary cardiovascular prevention.

AB - The Treating to New Targets (TNT) clinical trial found that intensive 80 mg atorvastatin (A80) treatment reduced cardiovascular events by 22% when compared to 10 mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding costs of care, when compared to the A10 treatment, in all three countries. The incremental cost per QALY gained was a,not sign 9,500, a,not sign 21,000, and a,not sign 15,000 in the UK, Spain, and Germany, respectively. Intensive A80 treatment is estimated to be cost-effective when compared to A10 treatment in secondary cardiovascular prevention.

KW - Cardiovascular disease

KW - Cholesterol lowering

KW - Cost-effectiveness

KW - Decision analysis

KW - Markov model

KW - Secondary prevention

KW - Statin therapy

KW - SCANDINAVIAN SIMVASTATIN SURVIVAL

KW - CORONARY-HEART-DISEASE

KW - MYOCARDIAL-INFARCTION

KW - CHOLESTEROL LEVELS

KW - CONTROLLED-TRIAL

KW - FOLLOW-UP

KW - 4S

KW - PRAVASTATIN

KW - GUIDELINES

KW - PROGNOSIS

UR - http://www.scopus.com/inward/record.url?scp=67649195258&partnerID=8YFLogxK

U2 - 10.1007/s10198-008-0126-1

DO - 10.1007/s10198-008-0126-1

M3 - Article

SN - 1618-7598

VL - 10

SP - 255

EP - 265

JO - European Journal of Health Economics

JF - European Journal of Health Economics

IS - 3

ER -

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Abstract

Keywords

Access to Document

Other files and links

Cite this